Patents by Inventor Edward B. Raskin

Edward B. Raskin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11957876
    Abstract: An automated blood glucose control system is configured to generate a backup therapy protocol comprising insulin therapy instructions derived from autonomously determined doses of insulin. The system generates a dose control signal using a control algorithm configured to autonomously determine doses of insulin to be infused into a subject for the purpose of controlling blood glucose of the subject based at least in part on a glucose level signal received from a glucose sensor. The system can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject as basal insulin, as correction boluses of insulin, or as mealtime boluses of insulin. The system can generate a backup injection therapy protocol or a backup pump therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: April 16, 2024
    Assignee: BETA BIONICS, INC.
    Inventors: Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano
  • Publication number: 20230166035
    Abstract: Automated glucose level control system that provide therapy to a subject, such as glucose control, are disclosed. The system generates dose control signals using control algorithms configured to autonomously determine doses of insulin to be infused into a subject. When the system determines that an initial dose control signal does not indicate health-appropriate therapy, the system can modify a manual therapy instruction and transmit an emergency dose control signal to the medicament pump. Disclosed systems and devices can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject. The system can generate a backup therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.
    Type: Application
    Filed: August 5, 2022
    Publication date: June 1, 2023
    Inventors: Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano, David Chi-Wai Lim, Edward B. Raskin
  • Publication number: 20220096748
    Abstract: An automated blood glucose control system can provide automatic delivery of glucose control therapy to a subject and receive information about manual glucose control therapy provided to the subject. The automated blood glucose control system can indicate an amount of a bolus of medicament via a control algorithm configured to control blood glucose level in the subject. The automated blood glucose control system can indicate an amount of a manual bolus of medicament, which can be used to model a diminishment of the medicament in the subject over time based at least in part on the manual bolus of medicament.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 31, 2022
    Inventors: Firas H. El-Khatib, Edward R. Damiano, Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, John R. Costik
  • Patent number: 11154656
    Abstract: An automated blood glucose control system can provide automatic delivery of glucose control therapy to a subject and receive information about manual glucose control therapy provided to the subject. The automated blood glucose control system can indicate an amount of a bolus of medicament via a control algorithm configured to control blood glucose level in the subject. The automated blood glucose control system can indicate an amount of a manual bolus of medicament, which can be used to model a diminishment of the medicament in the subject over time based at least in part on the manual bolus of medicament.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 26, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Firas H. El-Khatib, Edward R. Damiano, Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, John R. Costik
  • Publication number: 20210213200
    Abstract: An automated blood glucose control system is configured to generate a backup therapy protocol comprising insulin therapy instructions derived from autonomously determined doses of insulin. The system generates a dose control signal using a control algorithm configured to autonomously determine doses of insulin to be infused into a subject for the purpose of controlling blood glucose of the subject based at least in part on a glucose level signal received from a glucose sensor. The system can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject as basal insulin, as correction boluses of insulin, or as mealtime boluses of insulin. The system can generate a backup injection therapy protocol or a backup pump therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 15, 2021
    Inventors: Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano
  • Patent number: 10960137
    Abstract: An automated blood glucose control system is configured to generate a backup therapy protocol comprising insulin therapy instructions derived from autonomously determined doses of insulin. The system generates a dose control signal using a control algorithm configured to autonomously determine doses of insulin to be infused into a subject for the purpose of controlling blood glucose of the subject based at least in part on a glucose level signal received from a glucose sensor. The system can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject as basal insulin, as correction boluses of insulin, or as mealtime boluses of insulin. The system can generate a backup injection therapy protocol or a backup pump therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: March 30, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano
  • Publication number: 20210085868
    Abstract: An ambulatory medicament device can automatically resume medicament delivery after medicament delivery to a subject is suspended. Suspension of medicament delivery can occur for a temporary suspension period associated with a length of time that the delivery of the medicament is to be suspended. Resuming medicament delivery can occur upon determining that a resumption condition has occurred during the temporary suspension period.
    Type: Application
    Filed: October 2, 2020
    Publication date: March 25, 2021
    Inventors: David Chi-Wai Lim, Edward B. Raskin, Michael J. Rosinko, Edward R. Damiano, Firas H. El-Khatib, Himanshu Patel
  • Publication number: 20210085869
    Abstract: An automated blood glucose control system can provide automatic delivery of glucose control therapy to a subject and receive information about manual glucose control therapy provided to the subject. The automated blood glucose control system can indicate an amount of a bolus of medicament via a control algorithm configured to control blood glucose level in the subject. The automated blood glucose control system can indicate an amount of a manual bolus of medicament, which can be used to model a diminishment of the medicament in the subject over time based at least in part on the manual bolus of medicament.
    Type: Application
    Filed: October 2, 2020
    Publication date: March 25, 2021
    Inventors: Firas H. El-Khatib, Edward R. Damiano, Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, John R. Costik
  • Publication number: 20210016005
    Abstract: An automated blood glucose control system is configured to generate a backup therapy protocol comprising insulin therapy instructions derived from autonomously determined doses of insulin. The system generates a dose control signal using a control algorithm configured to autonomously determine doses of insulin to be infused into a subject for the purpose of controlling blood glucose of the subject based at least in part on a glucose level signal received from a glucose sensor. The system can track insulin therapy administered to the subject over a tracking period, including storing an indication of the autonomously determined doses of insulin delivered to the subject as basal insulin, as correction boluses of insulin, or as mealtime boluses of insulin. The system can generate a backup injection therapy protocol or a backup pump therapy protocol with insulin therapy instructions based at least in part on the insulin therapy administered to the subject over the tracking period.
    Type: Application
    Filed: October 2, 2020
    Publication date: January 21, 2021
    Inventors: Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, Firas H. El-Khatib, Edward R. Damiano